Market Cap 4.17B
Revenue (ttm) 290.52M
Net Income (ttm) 89.16M
EPS (ttm) N/A
PE Ratio 29.26
Forward PE 30.06
Profit Margin 30.69%
Debt to Equity Ratio 0.00
Volume 246,900
Avg Vol 380,866
Day's Range N/A - N/A
Shares Out 28.94M
Stochastic %K 69%
Beta 0.70
Analysts Strong Sell
Price Target $207.60

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treati...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 586 5830
Address:
2100 Wharton Street, Suite 701, Pittsburgh, United States
JarvisFlow
JarvisFlow Aug. 22 at 12:30 PM
Chardan Capital updates rating for Krystal Biotech ( $KRYS ) to Buy, target set at 219 → 216.
0 · Reply
kenny91655
kenny91655 Aug. 21 at 4:34 PM
$KRYS Didn't hear Krish touch on this yet In the first quarter of 2025, the Company and certain of its employees received subpoenas from the U.S. Department of Justice requesting that the Company produce certain documents regarding its sponsored genetic testing program relating to VYJUVEK and commercial practices relating thereto. The Company is cooperating and providing information in response to the subpoenas. It is not possible to estimate the amount of any loss or range of possible loss that might result from this inquiry, and because the final outcome cannot be predicted with certainty, unfavorable or unexpected developments or outcomes could result in a material impact to the Company’s results of operations.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 21 at 4:15 PM
$KRYS Krystal Biotech Granted An End Of Phase 2 Meeting With The FDA In October To Discuss Registration Path For Inhaled KB707 Following NSCLC Data
0 · Reply
ZManicItalian
ZManicItalian Aug. 14 at 8:17 PM
$KRYS $160+ incoming 🍻🐂
0 · Reply
ZManicItalian
ZManicItalian Aug. 13 at 2:08 PM
$KRYS like these green days 🤑
0 · Reply
ZManicItalian
ZManicItalian Aug. 12 at 11:17 PM
$KRYS let's get back above $160! Foreign markets on deck 🤑👍 🍻🐂
0 · Reply
LetsRide_
LetsRide_ Aug. 12 at 5:41 PM
$KRYS 👀
0 · Reply
enriquesaaa
enriquesaaa Aug. 6 at 3:00 PM
$KRYS It’ll happen soon. Probably some institution wanted in at lower prices and they dumped it with the excuse of lower q3. Maybe it was BoFA or any of their customers because they were first to reduce target price. We’re now in accumulation phase.
0 · Reply
LetsRide_
LetsRide_ Aug. 6 at 1:33 PM
$KRYS patiently waiting for a rebound..
0 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 5:52 PM
Citigroup has adjusted their stance on Krystal Biotech ( $KRYS ), setting the rating to Neutral with a target price of 176 → 166.
0 · Reply
Latest News on KRYS
Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 12:42 PM EDT - 18 days ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

May 6, 2025, 2:43 PM EDT - 3 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript


Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 24, 2025, 8:00 AM EDT - 4 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences


Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 7, 2025, 4:30 PM EDT - 4 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer


Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:43 AM EST - 6 months ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript


Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 27, 2024, 8:30 AM EST - 8 months ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy


Krystal Biotech to Present at Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 9 months ago

Krystal Biotech to Present at Upcoming Investor Conferences


Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 3:31 PM EST - 10 months ago

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:44 AM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:47 AM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript


JarvisFlow
JarvisFlow Aug. 22 at 12:30 PM
Chardan Capital updates rating for Krystal Biotech ( $KRYS ) to Buy, target set at 219 → 216.
0 · Reply
kenny91655
kenny91655 Aug. 21 at 4:34 PM
$KRYS Didn't hear Krish touch on this yet In the first quarter of 2025, the Company and certain of its employees received subpoenas from the U.S. Department of Justice requesting that the Company produce certain documents regarding its sponsored genetic testing program relating to VYJUVEK and commercial practices relating thereto. The Company is cooperating and providing information in response to the subpoenas. It is not possible to estimate the amount of any loss or range of possible loss that might result from this inquiry, and because the final outcome cannot be predicted with certainty, unfavorable or unexpected developments or outcomes could result in a material impact to the Company’s results of operations.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 21 at 4:15 PM
$KRYS Krystal Biotech Granted An End Of Phase 2 Meeting With The FDA In October To Discuss Registration Path For Inhaled KB707 Following NSCLC Data
0 · Reply
ZManicItalian
ZManicItalian Aug. 14 at 8:17 PM
$KRYS $160+ incoming 🍻🐂
0 · Reply
ZManicItalian
ZManicItalian Aug. 13 at 2:08 PM
$KRYS like these green days 🤑
0 · Reply
ZManicItalian
ZManicItalian Aug. 12 at 11:17 PM
$KRYS let's get back above $160! Foreign markets on deck 🤑👍 🍻🐂
0 · Reply
LetsRide_
LetsRide_ Aug. 12 at 5:41 PM
$KRYS 👀
0 · Reply
enriquesaaa
enriquesaaa Aug. 6 at 3:00 PM
$KRYS It’ll happen soon. Probably some institution wanted in at lower prices and they dumped it with the excuse of lower q3. Maybe it was BoFA or any of their customers because they were first to reduce target price. We’re now in accumulation phase.
0 · Reply
LetsRide_
LetsRide_ Aug. 6 at 1:33 PM
$KRYS patiently waiting for a rebound..
0 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 5:52 PM
Citigroup has adjusted their stance on Krystal Biotech ( $KRYS ), setting the rating to Neutral with a target price of 176 → 166.
0 · Reply
ZacksResearch
ZacksResearch Aug. 5 at 5:30 PM
$KRYS drops 14% despite Q2 beat — what's behind the slide? 📉 Krystal Biotech reported EPS of $1.29, topping the Zacks Consensus Estimate of $1.08, and revenues from sales of Vyjuvek surged 36.6% YoY. However, soft guidance for third-quarter revenues spooked investors, leading to the decline. Full breakdown here 👉 https://www.zacks.com/stock/news/2667254/krys-q2-earnings-and-sales-top-estimates-stock-down-on-q3-outlook?cid=sm-stocktwits-2-2667254-body-5966&ADID=SYND_STOCKTWITS_TWEET_2_2667254_BODY_5966
0 · Reply
ZacksResearch
ZacksResearch Aug. 5 at 1:27 PM
$KRYS beat Q2 on both earnings and sales — so why the 14% drop? 👀 Vyjuvek delivered strong numbers, but Q3 revenue guidance came in soft, spooking the Street. Full story here 👉 https://www.zacks.com/stock/news/2667254/krys-q2-earnings-and-sales-top-estimates-stock-down-on-q3-outlook?cid=sm-stocktwits-2-2667254-teaser-5934&ADID=SYND_STOCKTWITS_TWEET_2_2667254_TEASER_5934
0 · Reply
JarvisFlow
JarvisFlow Aug. 5 at 10:30 AM
Chardan Capital has adjusted their stance on Krystal Biotech ( $KRYS ), setting the rating to Buy with a target price of 219.
0 · Reply
EarningsCentral
EarningsCentral Aug. 5 at 3:15 AM
$KRYS Q2 FY25 Earnings Beat | VYJUVEK Margins, EU Launch, & KB707 Pipeline Update https://youtu.be/ZLvjYZ2Eb_U
0 · Reply
JackisBackAgain
JackisBackAgain Aug. 5 at 1:09 AM
$KRYS You guys can thank me later for this $PROP
1 · Reply
buymoremakemore
buymoremakemore Aug. 4 at 10:32 PM
$KRYS Wont be surprised to see rebound tomorrow
0 · Reply
TKkamen
TKkamen Aug. 4 at 8:18 PM
$KRYS I’m so confused. This is such an overreaction.
0 · Reply
LetsRide_
LetsRide_ Aug. 4 at 4:06 PM
$KRYS Overreaction.
0 · Reply
enriquesaaa
enriquesaaa Aug. 4 at 2:39 PM
$KRYS that they said that q3 earnings are gonna be below q2 due to patiente stopping treatment in the summer and also more expenses due to hiring of sales teams for Europe and Japan. They need to be trained but sales won’t go up until q4. But they said they remain seeing multi-year growth.
1 · Reply
rml360
rml360 Aug. 4 at 2:28 PM
$KRYS there is no growth story here anymore
0 · Reply
alexpitti
alexpitti Aug. 4 at 2:26 PM
$KRYS people are mentioning overreaction, but what was the bad news in the first place?
0 · Reply
Hbogati
Hbogati Aug. 4 at 2:24 PM
$KRYS using seasonality to raid shares. making profits and expanding to new markets. no real competition.
0 · Reply